Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Nebulized Corticosteroids in the Treatment of COPD Exacerbations: Systematic Review, Meta-Analysis, and Clinical Perspective.

Pleasants RA, Wang T, Xu X, Beiko T, Bei H, Zhai S, Drummond MB.

Respir Care. 2018 Oct;63(10):1302-1310. doi: 10.4187/respcare.06384. Review.

PMID:
30237276
2.

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease.

Pleasants RA 2nd.

Ann Pharmacother. 2018 Sep 1:1060028018798753. doi: 10.1177/1060028018798753. [Epub ahead of print]

PMID:
30175596
3.

Aerosol Delivery Devices for Obstructive Lung Diseases.

Pleasants RA, Hess DR.

Respir Care. 2018 Jun;63(6):708-733. doi: 10.4187/respcare.06290. Review.

PMID:
29794206
4.

Clinical Pharmacology of Oral Maintenance Therapies for Obstructive Lung Diseases.

Pleasants RA.

Respir Care. 2018 Jun;63(6):671-689. doi: 10.4187/respcare.06068. Review.

PMID:
29794203
5.

Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick®): A Review in Asthma.

Paik J, Scott LJ, Pleasants RA.

Clin Drug Investig. 2018 May;38(5):463-473. doi: 10.1007/s40261-018-0644-2. Review.

PMID:
29582249
6.

Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: a study based on pharmacovigilance data.

Xing Y, Zhang H, Sun S, Ma X, Pleasants RA, Tang H, Zheng H, Zhai S, Wang T.

Eur J Pediatr. 2018 Jan;177(1):145-154. doi: 10.1007/s00431-017-3048-z. Epub 2017 Nov 22.

7.

Assessing the impact of a remote digital coaching engagement program on patient-reported outcomes in asthma.

Rasulnia M, Burton BS, Ginter RP, Wang TY, Pleasants RA, Green CL, Lugogo N.

J Asthma. 2018 Jul;55(7):795-800. doi: 10.1080/02770903.2017.1362430. Epub 2017 Oct 11.

PMID:
28800273
8.

Dry Powder Inhalers and Humidity: Another Factor to Consider to Ensure Adequate Lung Delivery.

Pleasants RA.

Ann Am Thorac Soc. 2017 Oct;14(10):1602. doi: 10.1513/AnnalsATS.201706-454LE. No abstract available.

PMID:
28696775
9.

Empiric treatment against invasive fungal diseases in febrile neutropenic patients: a systematic review and network meta-analysis.

Chen K, Wang Q, Pleasants RA, Ge L, Liu W, Peng K, Zhai S.

BMC Infect Dis. 2017 Feb 20;17(1):159. doi: 10.1186/s12879-017-2263-6. Review.

10.

Defining and targeting health disparities in chronic obstructive pulmonary disease.

Pleasants RA, Riley IL, Mannino DM.

Int J Chron Obstruct Pulmon Dis. 2016 Oct 4;11:2475-2496. eCollection 2016. Review.

11.

Gender and asthma-chronic obstructive pulmonary disease overlap syndrome.

Wheaton AG, Pleasants RA, Croft JB, Ohar JA, Heidari K, Mannino DM, Liu Y, Strange C.

J Asthma. 2016 Sep;53(7):720-31. doi: 10.3109/02770903.2016.1154072. Epub 2016 Apr 6.

12.

Methods for using microblogs for health communication with a pharmacist-based account.

Wang T, Wang F, Xin X, Pleasants RA, Shi L.

Patient Educ Couns. 2016 Aug;99(8):1432-7. doi: 10.1016/j.pec.2016.03.003. Epub 2016 Mar 7.

PMID:
26979475
13.

Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis.

Pleasants RA, Wang T, Gao J, Tang H, Donohue JF.

Drugs. 2016 Mar;76(3):343-61. doi: 10.1007/s40265-015-0532-5. Review.

PMID:
26755180
14.

Targeting Persons With or At High Risk for Chronic Obstructive Pulmonary Disease by State-based Surveillance.

Pleasants RA, Heidari K, Wheaton AG, Ohar JA, Strange C, Croft JB, Liao W, Mannino DM, Kraft M.

COPD. 2015;12(6):680-9. doi: 10.3109/15412555.2015.1043424. Epub 2015 Sep 14.

15.

Smoking duration, respiratory symptoms, and COPD in adults aged ≥45 years with a smoking history.

Liu Y, Pleasants RA, Croft JB, Wheaton AG, Heidari K, Malarcher AM, Ohar JA, Kraft M, Mannino DM, Strange C.

Int J Chron Obstruct Pulmon Dis. 2015 Jul 21;10:1409-16. doi: 10.2147/COPD.S82259. eCollection 2015.

16.

Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease.

Liu Y, Pleasants RA, Croft JB, Lugogo N, Ohar J, Heidari K, Strange C, Wheaton AG, Mannino DM, Kraft M.

Respir Med. 2015 Jul;109(7):851-9. doi: 10.1016/j.rmed.2015.05.006. Epub 2015 May 16.

17.

Role of the fixed combination of fluticasone and salmeterol in adult Chinese patients with asthma and COPD.

Gao J, Pleasants RA.

Int J Chron Obstruct Pulmon Dis. 2015 Apr 15;10:775-89. doi: 10.2147/COPD.S80656. eCollection 2015. Review.

18.
19.

Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment.

Pleasants RA, Ohar JA, Croft JB, Liu Y, Kraft M, Mannino DM, Donohue JF, Herrick HL.

COPD. 2014 Jun;11(3):256-66. doi: 10.3109/15412555.2013.840571. Epub 2013 Oct 23.

PMID:
24152212
20.

Mortality from chronic obstructive pulmonary disease among adults aged 25 years or older in North Carolina.

Brown DW, Pleasants RA.

South Med J. 2011 Jan;104(1):20-3. doi: 10.1097/SMJ.0b013e3181fcda00.

PMID:
21119557
21.
22.

An update on chronic obstructive pulmonary disease.

Pleasants RA, Haden D.

Consult Pharm. 2005 Nov;20(11):965-75.

PMID:
16548673
23.

Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis.

Balkrishnan R, Nelsen LM, Kulkarni AS, Pleasants RA, Whitmire JT, Schechter MS.

J Asthma. 2005 Feb;42(1):35-40.

PMID:
15801326
24.

Pharmacokinetics of vancomycin in adult cystic fibrosis patients.

Pleasants RA, Michalets EL, Williams DM, Samuelson WM, Rehm JR, Knowles MR.

Antimicrob Agents Chemother. 1996 Jan;40(1):186-90.

25.

Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis.

Pleasants RA, Walker TR, Samuelson WM.

Chest. 1994 Oct;106(4):1124-8.

PMID:
7924483
26.

Drug allergies, adverse drug reactions, and the patient record.

Pleasants RA, Kessler JM.

Am J Hosp Pharm. 1993 Jul;50(7):1363. No abstract available.

PMID:
8362869
27.

Arthropathy secondary to ciprofloxacin in an adult cystic fibrosis patient.

Samuelson WM, Pleasants RA, Whitaker MS.

Ann Pharmacother. 1993 Mar;27(3):302-3.

PMID:
8453165
28.

Compatibility of ceftazidime and aminophylline admixtures for different methods of intravenous infusion.

Pleasants RA, Vaughan LM, Williams DM, Fox JL.

Ann Pharmacother. 1992 Oct;26(10):1221-6.

PMID:
1421642
29.

Use of antimicrobial drugs in adults before and after removal of a restriction policy.

Himmelberg CJ, Pleasants RA, Weber DJ, Kessler JM, Samsa GP, Spivey JM, Morris TL.

Am J Hosp Pharm. 1991 Jun;48(6):1220-7.

PMID:
1858800
30.

Influence of infusion method on serum tobramycin concentrations in adults with cystic fibrosis.

Pleasants RA, Williams DM, Waltner WE, Knowles MR.

Clin Pharm. 1990 Jul;9(7):541-5. No abstract available.

PMID:
2376111
31.

Simple conversion from intravenous aminophylline to twice daily oral theophylline.

Pleasants RA, Williams DM.

Chest. 1989 Dec;96(6):1440. No abstract available.

PMID:
2582862
32.

Comment: metered-dose inhalers.

Williams DM, Pleasants RA.

DICP. 1989 Oct;23(10):815-6. No abstract available.

PMID:
2815863
33.

Tobramycin administration and blood sampling through a dual-lumen peripheral intravenous catheter.

Pleasants RA, Williams DM, Fus AS, Leathers CM, Waltner WE.

DICP. 1989 Jun;23(6):460-3.

PMID:
2741479
34.

Reassessment of cross-reactivity of spironolactone metabolites with four digoxin immunoassays.

Pleasants RA, Williams DM, Porter RS, Gadsden RH Sr.

Ther Drug Monit. 1989;11(2):200-4.

PMID:
2655203
35.

Effect of four intravenous infusion methods on tobramycin pharmacokinetics.

Pleasants RA, Sawyer WT, Williams DM, McKenna WR, Powell JR.

Clin Pharm. 1988 May;7(5):374-9.

PMID:
3383543
36.

Accuracy of tobramycin delivery by four i.v. infusion methods.

Pleasants RA, Sawyer WT, Williams DM, McKenna WR, Brown JM, Powell JR.

Clin Pharm. 1988 May;7(5):367-73.

PMID:
3383542
37.

Effect of data collection method on results of serum digoxin concentration audit.

Makela EH, Davis SK, Piveral K, Miller WA, Pleasants RA, Gadsden RH Sr, Leman RB.

Am J Hosp Pharm. 1988 Jan;45(1):126-30.

PMID:
3348225
38.

Lack of apparent effect of assay methodology on the pharmacokinetics of digoxin.

Blum RA, DeVito JM, Pleasants RA, Crass RE, Gadsden RH Sr, Leman RB.

Ther Drug Monit. 1987 Dec;9(4):416-21.

PMID:
3424407
39.

Monitoring aminoglycoside serum concentrations.

Pleasants RA, Sawyer WT, Davidson EH.

South Med J. 1987 Feb;80(2):277-8. No abstract available.

PMID:
3810234
40.

Determination of clearance from a trough serum concentration at steady state.

Pleasants RA, Maddox RR, Crass RE, DeVito JM.

Drug Intell Clin Pharm. 1987 Jan;21(1 Pt 1):69-70. No abstract available.

PMID:
3816561
41.

Patient-location-specific alterations in aminoglycoside volume of distribution.

Pleasants RA, Sawyer WT, Dupuis RE, Crass RE.

Clin Pharm. 1986 Nov;5(11):873-4. No abstract available.

PMID:
3780157
42.

Interference of digoxin-like immunoreactive substances with three digoxin immunoassays in patients with various degrees of renal function.

Pleasants RA, Gadsden RH Sr, McCormack JP, Piveral K, Sawyer WT.

Clin Pharm. 1986 Oct;5(10):810-6.

PMID:
3780148
43.

Apparently raised serum creatinine levels due to cephalosporins.

Piveral K, Miller SC, Baird DR, Pleasants RA.

JAMA. 1986 Jan 17;255(3):323-4. No abstract available.

PMID:
3941511
44.

Estimation of the steady-state volume of distribution for digoxin: a comparison of model-independent methods with a two-compartment model in healthy volunteers.

De Vito JM, Crass RE, Blum RA, Pleasants RA, Schentag JJ.

Drug Intell Clin Pharm. 1985 Nov;19(11):837-9.

PMID:
4064918

Supplemental Content

Loading ...
Support Center